Biology Reference
In-Depth Information
Lek-Uthai, U., Suwanarusk, R., Ruengweerayut, R., Skinner-Adams, T.S., Nosten, F., et al.,
2008. Stronger activity of human immunodeficiency virus type 1 protease inhibitors
against clinical isolates of
Plasmodium vivax
than against those of
P. falciparum
. Antimicrob.
Agents Chemother. 52, 2435-2441.
Leslie, T., Rab, M.A., Ahmadzai, H., Durrani, N., Fayaz, M., et al., 2004. Compliance with
14-day primaquine therapy for radical cure of vivax malaria-a randomized placebo-
controlled trial comparing unsupervised with supervised treatment. Trans. R. Soc. Trop.
Med. Hyg. 98, 168-173.
Leslie, T., Mayan, I., Mohammed, N., Erasmus, P., Kolaczinski, J., et al., 2008. A randomised
trial of an eight-week, once weekly primaquine regimen to prevent relapse of
Plasmo-
dium vivax
in Northwest Frontier Province, Pakistan. PLoS ONE 3, 8.
LeYuan, S., QingXia, H., 2001. Observation on efficacy of pyronaridine phosphate and com-
bined with dihydroartemisinin for treatment of malaria in Eritrea, Africa. Chin. J. Para-
sitic. Dis. Control 14, R382. 331.
Li, X., Li, C., Che, L., Liu, X., Li, Z., et al., 1999. Observation on efficacy of artemether
compound against vivax malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong
Bing Za Zhi 17, 175-177.
Lomar, A.V.,Vidal, J.E., Lomar, F.P., Barbas, C.V., de Matos, G.J., et al., 2005. Acute respiratory
distress syndrome due to vivax malaria: case report and literature review. Braz. J. Infect.
Dis. 9, 425-430.
Lu, F., Gao, Q., Zhou, H., Cao, J., Wang, W., et al., 2011. Molecular test for vivax malaria
with loop-mediated isothermal amplification method in central China. Parasitol.
Res. 110, 2439-2444.
Lysenko, A.Y., 1960. Use of quinocide in treatment and prophylaxis of vivax malaria. Bull.
World Health Organ. 22, 641-662.
Maguire, J.D., Krisin, Marwoto, H., Richie, T.L., Fryauff, D.J., et al., 2006a. Mefloquine is
highly efficacious against chloroquine-resistant
Plasmodium vivax
malaria and
Plasmodium
falciparum
malaria in Papua, Indonesia. Clin. Infect. Dis. 42, 1067-1072.
Maguire, J.D., Lederman, E.R., Barcus, M.J., O'Meara, W.A., Jordon, R.G., et al., 2006b. Pro-
duction and validation of durable, high quality standardized malaria microscopy slides
for teaching, testing and quality assurance during an era of declining diagnostic profi-
ciency. Malar. J. 5, 92.
Maguire, J.D., Fenton, M.E., Susanti, A.I., Walker, J.B., 2007.
Plasmodium vivax
-associated
acute respiratory distress syndrome after extended travel in Afghanistan. Travel Med.
Infect. Dis. 5, 301-305.
Manning, L., Laman, M., Law, I., Bona, C., Aipit, S., et al., 2011. Features and prognosis of
severe malaria caused by
Plasmodium falciparum, Plasmodium vivax
and mixed
Plasmodium
species in Papua New Guinean children. PLoS ONE 6, e29203.
Marfurt, J., de Monbrison, F., Brega, S., Barbollat, L., Muller, I., et al., 2008. Molecular mark-
ers of in vivo
Plasmodium vivax
resistance to amodiaquine plus sulfadoxine-pyrimeth-
amine: mutations in pvdhfr and pvmdr1. J. Infect. Dis. 198, 409-417.
Marfurt, J., Chalfein, F., Prayoga, P., Wabiser, F., Kenangalem, E., et al., 2011a. Ex vivo activity
of histone deacetylase inhibitors against multidrug-resistant clinical isolates of
Plasmo-
dium falciparum
and
P. vivax
. Antimicrob. Agents Chemother. 55, 961-966.
Marfurt, J., Chalfein, F., Prayoga, P., Wabiser, F., Kenangalem, E., et al., 2011b. Ex vivo drug
susceptibility of ferroquine against chloroquine-resistant isolates of
Plasmodium falciparum
and
P. vivax
. Antimicrob. Agents Chemother. 55, 4461-4464.
Marsh, K., 2010. Research priorities for malaria elimination. Lancet 376, 1626-1627.
Mayxay, M., Thongpraseuth, V., Khanthavong, M., Lindegardh, N., Barends, M., et al., 2006.
An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-
piperaquine for the treatment of uncomplicated
Plasmodium falciparum
malaria in the Lao
People's Democratic Republic (Laos). Trop. Med. Int. Health 11, 1157-1165.
